| Trial ID: | L2591 |
| Source ID: | NCT01489644
|
| Associated Drug: |
Repaglinide
|
| Title: |
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide|DRUG: metformin|DRUG: repaglinide and metformin combination tablet
|
| Outcome Measures: |
Primary: Fasting repaglinide and metformin Area under the Curve (AUC) following NN4440 administration|Fasting repaglinide and metformin Area under the Curve (AUC) following individual administration|Fasting repaglinide and metformin Cmax (maximum drug concentration) following NN4440 administration|Fasting repaglinide and metformin Cmax (maximum drug concentration) following individual administration | Secondary: Repaglinide and metformin tmax (time to maximum) following individual administration fasting state|Repaglinide and metformin tmax (time to maximum) following NN4440 administration fasting state|Physical examinations|Vital signs
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
62
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-06
|
| Completion Date: |
2006-07
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-10
|
| Locations: |
Novo Nordisk Investigational Site, Miami, Florida, 33169, United States|Novo Nordisk Investigational Site, Tacoma, Washington, 98418, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01489644
|
